Compared with placebo, the smallest percentage body-weight loss was observed in individuals with type 2 diabetes, with an estimated treatment difference of 6.2% after 68 weeks of treatment [35], whereas an additional body-weight loss of 10.312.5% after 68 weeks of treatment (without prior run-in with semaglutide) was observed in individuals without diabetes in trials aiming to directly compare semaglutide with placebo [26, 36, 38, 39] (Fig
Many pharmaceutical manufacturers implement temperature monitoring systems with automated alarms to detect any deviations from acceptable storage ranges, preventing costly losses from equipment failures or power outages
PMID: 37 HaltomJTrovaoNSGuarnieriJVincentPSinghUTsoySet al
These patterns may indicate a separate gastrointestinal condition unrelated to GLP-1 therapy, or they may warrant a temporary dose reduction or switch to a different formulationoral semaglutide sometimes produces different digestive responses than injection, for example
Want to estimate whether your insurance may cover treatment
Talk about any side effects or concerns with GLP-1 medication
